A citation-based method for searching scientific literature

Zeynep Karakaya, Fatih Esad Topal, Firdes Topal, Umut Payza, Pınar Yeşim Akyol. Am J Emerg Med 2018
Times Cited: 6







List of co-cited articles
27 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity



Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
Yu-Mou Chou, Chen-June Seak, Zhong Ning Leonard Goh, Joanna Chen-Yeen Seak, Chen-Ken Seak, Chih-Chuan Lin. Medicine (Baltimore) 2018
19
66


Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin.
Shreya Pujara, Adriana Ioachimescu. J Investig Med High Impact Case Rep 2017
20
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Ketoacidosis with euglycemia in a patient with type 2 diabetes mellitus taking dapagliflozin: A case report.
Sang Mok Yeo, Hayeon Park, Jin Hyuk Paek, Woo Yeong Park, Seungyeup Han, Sung Bae Park, Kyubok Jin. Medicine (Baltimore) 2019
8
50

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications.
George L Bakris, Vivian A Fonseca, Kumar Sharma, Ernest M Wright. Kidney Int 2009
216
50

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
462
50

Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Jenny E Blau, Sri Harsha Tella, Simeon I Taylor, Kristina I Rother. Diabetes Metab Res Rev 2017
97
33



SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
295
33

Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin.
Junichiro Adachi, Yuusuke Inaba, Chisato Maki. Intern Med 2017
15
33

Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
Morten Gram Pedersen, Ingela Ahlstedt, Mickaël F El Hachmane, Sven O Göpel. Sci Rep 2016
42
33

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin.
Daniel A Kelmenson, Kelsey Burr, Yusra Azhar, Paul Reynolds, Chelsea A Baker, Neda Rasouli. J Investig Med High Impact Case Rep 2017
20
33

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
418
33

Diabetic Ketoacidosis With Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Patients With Type 1 Diabetes.
Anne L Peters, Robert R Henry, Payal Thakkar, Cindy Tong, Maria Alba. Diabetes Care 2016
61
33


SGLT2 Inhibitors and Cardiovascular Outcomes: Current Perspectives and Future Potentials.
Xiaoming Jia, Paras B Mehta, Yumei Ye, Mahboob Alam, Yochai Birnbaum, Mandeep Bajaj. Curr Diab Rep 2018
9
33

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program.
Ngozi Erondu, Mehul Desai, Kirk Ways, Gary Meininger. Diabetes Care 2015
207
33

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.
Yehuda Handelsman, Robert R Henry, Zachary T Bloomgarden, Sam Dagogo-Jack, Ralph A DeFronzo, Daniel Einhorn, Ele Ferrannini, Vivian A Fonseca, Alan J Garber, George Grunberger,[...]. Endocr Pract 2016
183
33


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
T Heise, E Seewaldt-Becker, S Macha, S Hantel, S Pinnetti, L Seman, H J Woerle. Diabetes Obes Metab 2013
190
33

SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis: A Case Report.
Katherine M Wang, Robert T Isom. Kidney Med 2020
14
33


SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats.
Masanori Yokono, Toshiyuki Takasu, Yuka Hayashizaki, Keisuke Mitsuoka, Rumi Kihara, Yuko Muramatsu, Sousuke Miyoshi, Atsuo Tahara, Eiji Kurosaki, Qun Li,[...]. Eur J Pharmacol 2014
128
16

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Atsuo Tahara, Toshiyuki Takasu, Masanori Yokono, Masakazu Imamura, Eiji Kurosaki. J Pharmacol Sci 2016
24
16

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
David Fitchett, Javed Butler, Philippe van de Borne, Bernard Zinman, John M Lachin, Christoph Wanner, Hans J Woerle, Stefan Hantel, Jyothis T George, Odd Erik Johansen,[...]. Eur Heart J 2018
164
16

Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis.
Rachel J Perry, Xian-Man Zhang, Dongyan Zhang, Naoki Kumashiro, Joao-Paulo G Camporez, Gary W Cline, Douglas L Rothman, Gerald I Shulman. Nat Med 2014
137
16

Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ele Ferrannini, Simona Baldi, Silvia Frascerra, Brenno Astiarraga, Tim Heise, Roberto Bizzotto, Andrea Mari, Thomas R Pieber, Elza Muscelli. Diabetes 2016
344
16

Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes.
H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
493
16

Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Elza Muscelli, Brenno Astiarraga, Elisabetta Barsotti, Andrea Mari, Freimut Schliess, Leszek Nosek, Tim Heise, Uli C Broedl, Hans-Juergen Woerle, Ele Ferrannini. Diabetologia 2016
16
16


Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication.
Giuseppe Mancia, Christopher P Cannon, Ilkka Tikkanen, Cordula Zeller, Ludwin Ley, Hans J Woerle, Uli C Broedl, Odd Erik Johansen. Hypertension 2016
70
16

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models.
M Suzuki, M Takeda, A Kito, M Fukazawa, T Yata, M Yamamoto, T Nagata, T Fukuzawa, M Yamane, K Honda,[...]. Nutr Diabetes 2014
70
16


Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes.
Rachel J Perry, João-Paulo G Camporez, Romy Kursawe, Paul M Titchenell, Dongyan Zhang, Curtis J Perry, Michael J Jurczak, Abulizi Abudukadier, Myoung Sook Han, Xian-Man Zhang,[...]. Cell 2015
409
16

SGLT-2 inhibition and glucagon: Cause for alarm?
Richard G Kibbey. Trends Endocrinol Metab 2015
24
16




SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
161
16

Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease.
David Fitchett, Silvio E Inzucchi, John M Lachin, Christoph Wanner, Philippe van de Borne, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Jyothis T George,[...]. J Am Coll Cardiol 2018
25
16

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N Engl J Med 2017
159
16


EMPA-REG: Glucose excretion and lipid mobilization - not storage - saves lives.
Nils Bruun Jørgensen, Jens Pedersen, Allan Arthur Vaag. J Diabetes Complications 2016
8
16

Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
A Solini, G Sebastiani, L Nigi, E Santini, C Rossi, F Dotta. Diabetes Metab 2017
40
16



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.